| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 111 | 2023 | 1385 | 12.920 |
Why?
|
| Carcinoma, Endometrioid | 43 | 2022 | 327 | 7.460 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 36 | 2023 | 481 | 6.890 |
Why?
|
| DNA Mismatch Repair | 15 | 2023 | 283 | 2.970 |
Why?
|
| Microsatellite Instability | 24 | 2023 | 408 | 2.550 |
Why?
|
| MutL Protein Homolog 1 | 15 | 2023 | 206 | 1.940 |
Why?
|
| Biomarkers, Tumor | 50 | 2021 | 10708 | 1.900 |
Why?
|
| PTEN Phosphohydrolase | 20 | 2016 | 1012 | 1.840 |
Why?
|
| Endometrium | 24 | 2022 | 457 | 1.640 |
Why?
|
| Endometrial Hyperplasia | 16 | 2020 | 122 | 1.590 |
Why?
|
| Mutation | 58 | 2022 | 15912 | 1.470 |
Why?
|
| Colorectal Neoplasms | 22 | 2023 | 3707 | 1.450 |
Why?
|
| DNA Mutational Analysis | 26 | 2019 | 2357 | 1.430 |
Why?
|
| Cystadenocarcinoma, Serous | 15 | 2017 | 499 | 1.400 |
Why?
|
| Ovarian Neoplasms | 35 | 2018 | 4795 | 1.340 |
Why?
|
| Immunohistochemistry | 42 | 2019 | 7655 | 1.330 |
Why?
|
| beta Catenin | 7 | 2022 | 683 | 1.300 |
Why?
|
| Uterine Neoplasms | 14 | 2020 | 576 | 1.280 |
Why?
|
| High-Throughput Nucleotide Sequencing | 25 | 2021 | 2359 | 1.280 |
Why?
|
| DNA Methylation | 15 | 2023 | 2765 | 1.170 |
Why?
|
| Female | 216 | 2023 | 148940 | 1.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 18 | 2022 | 1470 | 1.120 |
Why?
|
| Genetic Testing | 8 | 2017 | 1696 | 1.070 |
Why?
|
| Neoplasms, Multiple Primary | 7 | 2014 | 557 | 0.940 |
Why?
|
| MutS Homolog 2 Protein | 12 | 2020 | 179 | 0.870 |
Why?
|
| Humans | 236 | 2023 | 270740 | 0.860 |
Why?
|
| Neoplasm Proteins | 13 | 2018 | 3345 | 0.860 |
Why?
|
| Estrogens | 11 | 2020 | 805 | 0.860 |
Why?
|
| Gene Expression Regulation, Neoplastic | 36 | 2020 | 9042 | 0.810 |
Why?
|
| Hysterectomy | 7 | 2020 | 654 | 0.800 |
Why?
|
| DNA-Binding Proteins | 19 | 2020 | 5002 | 0.800 |
Why?
|
| Neoplastic Syndromes, Hereditary | 3 | 2021 | 232 | 0.780 |
Why?
|
| Obesity | 10 | 2022 | 2904 | 0.760 |
Why?
|
| Receptors, Progesterone | 17 | 2022 | 1604 | 0.750 |
Why?
|
| Middle Aged | 110 | 2021 | 90352 | 0.750 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 10 | 2022 | 1281 | 0.740 |
Why?
|
| Proto-Oncogene Proteins B-raf | 11 | 2018 | 1336 | 0.720 |
Why?
|
| Aged | 93 | 2021 | 73333 | 0.700 |
Why?
|
| Cervix Uteri | 3 | 2019 | 247 | 0.700 |
Why?
|
| Peritoneal Neoplasms | 5 | 2015 | 859 | 0.690 |
Why?
|
| Adult | 101 | 2023 | 82040 | 0.680 |
Why?
|
| Progesterone | 8 | 2022 | 711 | 0.650 |
Why?
|
| NF-kappa B | 3 | 2019 | 1563 | 0.620 |
Why?
|
| Aged, 80 and over | 51 | 2021 | 30998 | 0.600 |
Why?
|
| Adenocarcinoma | 19 | 2019 | 7914 | 0.600 |
Why?
|
| Metformin | 6 | 2019 | 393 | 0.600 |
Why?
|
| S100 Proteins | 2 | 2009 | 186 | 0.600 |
Why?
|
| Germ-Line Mutation | 7 | 2016 | 1101 | 0.570 |
Why?
|
| Nuclear Proteins | 12 | 2017 | 3438 | 0.570 |
Why?
|
| Mixed Tumor, Mullerian | 3 | 2007 | 37 | 0.560 |
Why?
|
| Gene Expression Profiling | 16 | 2021 | 5149 | 0.550 |
Why?
|
| DNA Repair Enzymes | 4 | 2014 | 238 | 0.540 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 1032 | 0.540 |
Why?
|
| Lynch Syndrome II | 1 | 2016 | 3 | 0.540 |
Why?
|
| Tumor Suppressor Proteins | 12 | 2022 | 1903 | 0.540 |
Why?
|
| Immunoenzyme Techniques | 10 | 2014 | 1189 | 0.540 |
Why?
|
| 5'-Nucleotidase | 1 | 2016 | 63 | 0.530 |
Why?
|
| Keratin-7 | 1 | 2016 | 48 | 0.530 |
Why?
|
| Precision Medicine | 7 | 2019 | 1207 | 0.530 |
Why?
|
| Neoplasm Staging | 31 | 2022 | 14012 | 0.520 |
Why?
|
| Androgens | 1 | 2019 | 506 | 0.510 |
Why?
|
| Signal Transduction | 26 | 2018 | 12103 | 0.500 |
Why?
|
| Circulating Tumor DNA | 1 | 2018 | 274 | 0.500 |
Why?
|
| Neoplasms | 22 | 2021 | 15927 | 0.490 |
Why?
|
| Neoplasm Grading | 12 | 2020 | 1823 | 0.480 |
Why?
|
| Adenosine | 1 | 2016 | 294 | 0.470 |
Why?
|
| Gene Expression | 11 | 2020 | 3640 | 0.460 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2019 | 5776 | 0.450 |
Why?
|
| Receptors, Androgen | 1 | 2019 | 854 | 0.430 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2013 | 49 | 0.430 |
Why?
|
| Contraceptives, Oral | 1 | 2013 | 57 | 0.430 |
Why?
|
| Pathology, Clinical | 1 | 2014 | 129 | 0.430 |
Why?
|
| Phosphatidylinositol 3-Kinases | 12 | 2016 | 1710 | 0.420 |
Why?
|
| Intrauterine Devices, Medicated | 3 | 2020 | 38 | 0.420 |
Why?
|
| Levonorgestrel | 3 | 2020 | 53 | 0.420 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2019 | 1655 | 0.410 |
Why?
|
| Progestins | 3 | 2010 | 92 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2023 | 10400 | 0.410 |
Why?
|
| Estrogen Receptor alpha | 6 | 2018 | 692 | 0.400 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2010 | 1903 | 0.400 |
Why?
|
| Prognosis | 34 | 2019 | 22505 | 0.400 |
Why?
|
| Transcriptional Activation | 3 | 2014 | 1111 | 0.390 |
Why?
|
| Receptors, Estrogen | 10 | 2019 | 2170 | 0.380 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 1089 | 0.380 |
Why?
|
| Cytodiagnosis | 3 | 2021 | 201 | 0.370 |
Why?
|
| PPAR delta | 3 | 2019 | 53 | 0.370 |
Why?
|
| Cell Proliferation | 22 | 2019 | 7238 | 0.370 |
Why?
|
| Gene Fusion | 3 | 2021 | 214 | 0.370 |
Why?
|
| Carcinoma, Papillary | 4 | 2015 | 566 | 0.370 |
Why?
|
| Cell Line, Tumor | 32 | 2020 | 14849 | 0.360 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 4 | 2019 | 617 | 0.360 |
Why?
|
| DNA, Neoplasm | 8 | 2018 | 1958 | 0.360 |
Why?
|
| Granulosa Cell Tumor | 2 | 2023 | 81 | 0.360 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2010 | 143 | 0.360 |
Why?
|
| Adenocarcinoma, Clear Cell | 5 | 2017 | 176 | 0.360 |
Why?
|
| Carcinoma | 7 | 2019 | 2610 | 0.350 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2020 | 3658 | 0.340 |
Why?
|
| Molecular Targeted Therapy | 9 | 2019 | 2399 | 0.340 |
Why?
|
| Antineoplastic Agents | 18 | 2017 | 14617 | 0.320 |
Why?
|
| Young Adult | 21 | 2021 | 22251 | 0.320 |
Why?
|
| Thyroid Neoplasms | 4 | 2019 | 1894 | 0.310 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 15 | 2017 | 3597 | 0.310 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2013 | 841 | 0.310 |
Why?
|
| ras Proteins | 5 | 2017 | 804 | 0.310 |
Why?
|
| Arachidonate 15-Lipoxygenase | 4 | 2012 | 92 | 0.310 |
Why?
|
| Early Detection of Cancer | 5 | 2017 | 1340 | 0.300 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2009 | 293 | 0.300 |
Why?
|
| Neoplasm Invasiveness | 12 | 2019 | 4048 | 0.290 |
Why?
|
| Pyrimidines | 8 | 2020 | 3669 | 0.290 |
Why?
|
| Microsatellite Repeats | 8 | 2017 | 627 | 0.290 |
Why?
|
| Cohort Studies | 13 | 2020 | 9470 | 0.290 |
Why?
|
| Protein Kinases | 4 | 2019 | 902 | 0.290 |
Why?
|
| Brain Neoplasms | 3 | 2021 | 4958 | 0.290 |
Why?
|
| TOR Serine-Threonine Kinases | 10 | 2016 | 1563 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-akt | 11 | 2018 | 2069 | 0.280 |
Why?
|
| Animals | 52 | 2020 | 61956 | 0.270 |
Why?
|
| Protein Transport | 5 | 2018 | 737 | 0.270 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 6 | 2019 | 529 | 0.270 |
Why?
|
| Stress, Physiological | 1 | 2010 | 486 | 0.270 |
Why?
|
| Phosphorylation | 16 | 2019 | 4942 | 0.270 |
Why?
|
| Receptor, EphA2 | 3 | 2014 | 138 | 0.270 |
Why?
|
| Celiac Disease | 1 | 2007 | 77 | 0.270 |
Why?
|
| Melanoma | 7 | 2019 | 5595 | 0.260 |
Why?
|
| Retrospective Studies | 26 | 2022 | 39890 | 0.260 |
Why?
|
| Adenosine Triphosphatases | 4 | 2014 | 427 | 0.260 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 3 | 2016 | 299 | 0.260 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 4 | 2014 | 49 | 0.260 |
Why?
|
| Colonic Neoplasms | 6 | 2014 | 1435 | 0.250 |
Why?
|
| Leiomyoma | 2 | 2004 | 161 | 0.250 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2017 | 107 | 0.250 |
Why?
|
| Mice | 38 | 2019 | 35600 | 0.250 |
Why?
|
| Follow-Up Studies | 13 | 2019 | 15218 | 0.250 |
Why?
|
| Specimen Handling | 2 | 2018 | 307 | 0.240 |
Why?
|
| Pathologists | 2 | 2023 | 101 | 0.240 |
Why?
|
| Carcinoid Tumor | 2 | 2005 | 282 | 0.240 |
Why?
|
| Cell Movement | 7 | 2019 | 2472 | 0.240 |
Why?
|
| Transforming Growth Factor beta | 2 | 2013 | 1109 | 0.240 |
Why?
|
| Cell Transformation, Neoplastic | 8 | 2019 | 2453 | 0.240 |
Why?
|
| Male | 55 | 2021 | 128315 | 0.240 |
Why?
|
| Polymerase Chain Reaction | 6 | 2017 | 3476 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2010 | 5593 | 0.240 |
Why?
|
| Neoplasm Metastasis | 8 | 2021 | 5315 | 0.240 |
Why?
|
| Transcription Factors | 12 | 2018 | 5438 | 0.240 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2007 | 368 | 0.240 |
Why?
|
| Adolescent | 23 | 2021 | 32767 | 0.240 |
Why?
|
| RNA, Messenger | 16 | 2014 | 6390 | 0.240 |
Why?
|
| Down-Regulation | 8 | 2017 | 2090 | 0.230 |
Why?
|
| Liver Neoplasms | 7 | 2019 | 4821 | 0.230 |
Why?
|
| Genotype | 5 | 2023 | 4252 | 0.230 |
Why?
|
| Genomics | 7 | 2017 | 2835 | 0.230 |
Why?
|
| Eflornithine | 1 | 2004 | 60 | 0.230 |
Why?
|
| Apoptosis | 13 | 2019 | 7757 | 0.230 |
Why?
|
| Body Mass Index | 6 | 2020 | 2232 | 0.230 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2014 | 2617 | 0.220 |
Why?
|
| Fenretinide | 1 | 2004 | 100 | 0.220 |
Why?
|
| Estradiol | 4 | 2013 | 827 | 0.220 |
Why?
|
| Age of Onset | 4 | 2020 | 853 | 0.220 |
Why?
|
| Autophagy | 1 | 2010 | 911 | 0.220 |
Why?
|
| Neoplasms, Second Primary | 4 | 2010 | 1388 | 0.220 |
Why?
|
| Sequence Analysis, DNA | 6 | 2018 | 2573 | 0.220 |
Why?
|
| Duodenum | 2 | 2019 | 169 | 0.220 |
Why?
|
| Colon | 6 | 2017 | 659 | 0.220 |
Why?
|
| Receptor, ErbB-2 | 5 | 2018 | 2651 | 0.220 |
Why?
|
| Case-Control Studies | 8 | 2019 | 6224 | 0.220 |
Why?
|
| Pancreatic Neoplasms | 6 | 2019 | 5257 | 0.220 |
Why?
|
| Membrane Proteins | 6 | 2021 | 2928 | 0.220 |
Why?
|
| Sirolimus | 4 | 2014 | 831 | 0.220 |
Why?
|
| Gene Amplification | 5 | 2017 | 766 | 0.210 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2020 | 689 | 0.210 |
Why?
|
| Fallopian Tube Neoplasms | 3 | 2014 | 155 | 0.210 |
Why?
|
| Cell Differentiation | 7 | 2017 | 4116 | 0.210 |
Why?
|
| Wolffian Ducts | 1 | 2002 | 24 | 0.210 |
Why?
|
| Gene Deletion | 7 | 2017 | 1474 | 0.210 |
Why?
|
| Hemorrhoids | 1 | 2002 | 14 | 0.210 |
Why?
|
| Stem Cells | 2 | 2019 | 1216 | 0.200 |
Why?
|
| RNA, Neoplasm | 3 | 2021 | 805 | 0.200 |
Why?
|
| Prospective Studies | 9 | 2018 | 13414 | 0.200 |
Why?
|
| Omentum | 2 | 2013 | 108 | 0.200 |
Why?
|
| Premenopause | 3 | 2020 | 136 | 0.200 |
Why?
|
| Genome, Human | 3 | 2017 | 1888 | 0.200 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2019 | 485 | 0.200 |
Why?
|
| Combined Modality Therapy | 7 | 2020 | 9039 | 0.190 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 124 | 0.190 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2019 | 153 | 0.190 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2004 | 242 | 0.190 |
Why?
|
| Repressor Proteins | 4 | 2019 | 1718 | 0.190 |
Why?
|
| Cell Polarity | 3 | 2018 | 212 | 0.190 |
Why?
|
| GTP Phosphohydrolases | 2 | 2021 | 339 | 0.190 |
Why?
|
| DNA Repair | 2 | 2008 | 1909 | 0.180 |
Why?
|
| Mice, Knockout | 9 | 2019 | 5728 | 0.180 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2021 | 1402 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 9 | 2020 | 7100 | 0.180 |
Why?
|
| Hypoglycemic Agents | 2 | 2016 | 599 | 0.180 |
Why?
|
| Cytological Techniques | 1 | 2020 | 69 | 0.180 |
Why?
|
| Disease-Free Survival | 7 | 2017 | 10265 | 0.180 |
Why?
|
| Gene Silencing | 5 | 2013 | 827 | 0.180 |
Why?
|
| Cell Nucleus | 5 | 2018 | 1712 | 0.180 |
Why?
|
| Cyclopentanes | 1 | 2020 | 42 | 0.170 |
Why?
|
| Homologous Recombination | 1 | 2021 | 187 | 0.170 |
Why?
|
| Estrogen Receptor beta | 2 | 2014 | 149 | 0.170 |
Why?
|
| Neovascularization, Pathologic | 4 | 2017 | 1586 | 0.170 |
Why?
|
| Fallopian Tubes | 2 | 2014 | 129 | 0.170 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2012 | 517 | 0.170 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2017 | 1002 | 0.170 |
Why?
|
| Boron Compounds | 1 | 2020 | 72 | 0.170 |
Why?
|
| Mutation Rate | 2 | 2017 | 220 | 0.170 |
Why?
|
| Transcriptome | 5 | 2021 | 1963 | 0.170 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 9 | 2017 | 2471 | 0.170 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 3 | 2005 | 153 | 0.170 |
Why?
|
| Organ Sparing Treatments | 2 | 2019 | 283 | 0.170 |
Why?
|
| Gene Knockdown Techniques | 3 | 2016 | 1076 | 0.160 |
Why?
|
| GPI-Linked Proteins | 2 | 2016 | 232 | 0.160 |
Why?
|
| Carrier Proteins | 5 | 2016 | 2098 | 0.160 |
Why?
|
| Biopsy | 5 | 2021 | 3484 | 0.160 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2009 | 94 | 0.160 |
Why?
|
| rac1 GTP-Binding Protein | 2 | 2016 | 110 | 0.160 |
Why?
|
| S100 Calcium-Binding Protein A4 | 2 | 2009 | 51 | 0.160 |
Why?
|
| Neurofibromin 2 | 1 | 2018 | 40 | 0.160 |
Why?
|
| B7 Antigens | 1 | 2019 | 84 | 0.150 |
Why?
|
| Adipose Tissue | 2 | 2013 | 715 | 0.150 |
Why?
|
| Primate Diseases | 1 | 2018 | 21 | 0.150 |
Why?
|
| Receptor, ErbB-3 | 1 | 2018 | 126 | 0.150 |
Why?
|
| Anus Neoplasms | 1 | 2002 | 414 | 0.150 |
Why?
|
| Healthy Lifestyle | 1 | 2018 | 42 | 0.150 |
Why?
|
| Gonanes | 1 | 2017 | 50 | 0.150 |
Why?
|
| Neuroendocrine Tumors | 2 | 2014 | 656 | 0.150 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2019 | 131 | 0.150 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 676 | 0.150 |
Why?
|
| Loss of Heterozygosity | 4 | 2019 | 623 | 0.150 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 5162 | 0.150 |
Why?
|
| Epithelial Cells | 6 | 2018 | 1875 | 0.150 |
Why?
|
| Fasting | 1 | 2019 | 342 | 0.150 |
Why?
|
| Parathyroid Neoplasms | 1 | 2019 | 190 | 0.150 |
Why?
|
| Glycine | 1 | 2020 | 322 | 0.150 |
Why?
|
| Transcription Factor TFIID | 1 | 2017 | 27 | 0.150 |
Why?
|
| TATA-Binding Protein Associated Factors | 1 | 2017 | 27 | 0.140 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 30 | 0.140 |
Why?
|
| RNA, Small Interfering | 6 | 2019 | 2196 | 0.140 |
Why?
|
| Weight Reduction Programs | 1 | 2018 | 74 | 0.140 |
Why?
|
| Equilin | 2 | 2009 | 5 | 0.140 |
Why?
|
| Histone Acetyltransferases | 2 | 2017 | 433 | 0.140 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2003 | 743 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 334 | 0.140 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2010 | 530 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2022 | 2271 | 0.140 |
Why?
|
| Stem Cell Transplantation | 2 | 2018 | 1418 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-kit | 4 | 2014 | 484 | 0.140 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2015 | 2386 | 0.140 |
Why?
|
| Oncogene Fusion | 1 | 2016 | 62 | 0.140 |
Why?
|
| Reproducibility of Results | 8 | 2021 | 6177 | 0.140 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2018 | 442 | 0.140 |
Why?
|
| Pathology Department, Hospital | 1 | 2016 | 15 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2020 | 1269 | 0.140 |
Why?
|
| Piperazines | 5 | 2012 | 2145 | 0.140 |
Why?
|
| Uterus | 5 | 2017 | 798 | 0.130 |
Why?
|
| Exome | 4 | 2017 | 1248 | 0.130 |
Why?
|
| Laboratories | 1 | 2017 | 132 | 0.130 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 512 | 0.130 |
Why?
|
| Ovary | 3 | 2018 | 688 | 0.130 |
Why?
|
| Wnt Signaling Pathway | 2 | 2020 | 444 | 0.130 |
Why?
|
| Carcinosarcoma | 1 | 2017 | 145 | 0.130 |
Why?
|
| Research Report | 1 | 2017 | 136 | 0.130 |
Why?
|
| Proteome | 1 | 2020 | 571 | 0.130 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2016 | 66 | 0.130 |
Why?
|
| Rats | 8 | 2016 | 6441 | 0.130 |
Why?
|
| Stomach | 1 | 2019 | 402 | 0.130 |
Why?
|
| Mucin-4 | 1 | 2015 | 17 | 0.130 |
Why?
|
| Polycomb-Group Proteins | 1 | 2015 | 42 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2019 | 16689 | 0.130 |
Why?
|
| Placentation | 1 | 2016 | 61 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2019 | 4961 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-abl | 3 | 2005 | 84 | 0.130 |
Why?
|
| Cisplatin | 2 | 2019 | 2497 | 0.130 |
Why?
|
| Ki-67 Antigen | 5 | 2020 | 675 | 0.130 |
Why?
|
| Radiation Tolerance | 1 | 2019 | 639 | 0.130 |
Why?
|
| Disease Progression | 9 | 2019 | 6867 | 0.130 |
Why?
|
| Macaca mulatta | 1 | 2018 | 715 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 8 | 2016 | 3216 | 0.130 |
Why?
|
| Carcinogenesis | 2 | 2019 | 1033 | 0.130 |
Why?
|
| Infertility, Female | 3 | 2018 | 209 | 0.130 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2016 | 100 | 0.130 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2017 | 185 | 0.130 |
Why?
|
| Mucin-1 | 1 | 2016 | 158 | 0.130 |
Why?
|
| Ideal Body Weight | 1 | 2015 | 8 | 0.130 |
Why?
|
| MicroRNAs | 4 | 2014 | 2887 | 0.130 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 2 | 2014 | 28 | 0.130 |
Why?
|
| Genitalia, Female | 1 | 2016 | 83 | 0.130 |
Why?
|
| Histone Deacetylases | 2 | 2009 | 364 | 0.130 |
Why?
|
| Transplant Recipients | 1 | 2018 | 337 | 0.130 |
Why?
|
| Breast Neoplasms, Male | 1 | 2017 | 232 | 0.130 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2014 | 347 | 0.120 |
Why?
|
| Kidney Neoplasms | 2 | 2015 | 3108 | 0.120 |
Why?
|
| Thiazoles | 3 | 2019 | 723 | 0.120 |
Why?
|
| Urologic Neoplasms | 1 | 2017 | 202 | 0.120 |
Why?
|
| Genetic Variation | 2 | 2017 | 2166 | 0.120 |
Why?
|
| Genital Neoplasms, Female | 1 | 2002 | 794 | 0.120 |
Why?
|
| Gastric Mucosa | 1 | 2019 | 660 | 0.120 |
Why?
|
| DNA Copy Number Variations | 3 | 2017 | 1568 | 0.120 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2019 | 497 | 0.120 |
Why?
|
| Thiazolidinediones | 2 | 2008 | 147 | 0.120 |
Why?
|
| Cytokines | 3 | 2019 | 2825 | 0.120 |
Why?
|
| ADAM Proteins | 1 | 2015 | 114 | 0.120 |
Why?
|
| Receptors, Notch | 1 | 2017 | 372 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2019 | 1179 | 0.120 |
Why?
|
| Research | 1 | 2017 | 427 | 0.120 |
Why?
|
| Embryo Implantation | 3 | 2016 | 289 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2020 | 6256 | 0.120 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2017 | 232 | 0.120 |
Why?
|
| Protein Isoforms | 3 | 2013 | 848 | 0.120 |
Why?
|
| Cluster Analysis | 3 | 2015 | 1075 | 0.120 |
Why?
|
| Risk Factors | 10 | 2020 | 17888 | 0.120 |
Why?
|
| Epithelium | 3 | 2013 | 782 | 0.120 |
Why?
|
| Lymph Nodes | 4 | 2013 | 3077 | 0.120 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2016 | 1126 | 0.120 |
Why?
|
| Standard of Care | 1 | 2016 | 277 | 0.120 |
Why?
|
| Estrone | 3 | 2009 | 32 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 9 | 2013 | 5759 | 0.120 |
Why?
|
| Estrogens, Conjugated (USP) | 3 | 2009 | 32 | 0.120 |
Why?
|
| Lung Neoplasms | 4 | 2019 | 12033 | 0.110 |
Why?
|
| Organ Specificity | 1 | 2015 | 737 | 0.110 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 797 | 0.110 |
Why?
|
| Cystadenocarcinoma, Papillary | 2 | 2004 | 82 | 0.110 |
Why?
|
| Drugs, Investigational | 1 | 2015 | 130 | 0.110 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2016 | 631 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2014 | 85 | 0.110 |
Why?
|
| Eye Neoplasms | 1 | 2016 | 257 | 0.110 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2015 | 204 | 0.110 |
Why?
|
| Adenomyosis | 1 | 2013 | 10 | 0.110 |
Why?
|
| HCT116 Cells | 3 | 2020 | 354 | 0.110 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 135 | 0.110 |
Why?
|
| Hyperplasia | 4 | 2022 | 564 | 0.110 |
Why?
|
| Smad4 Protein | 1 | 2015 | 201 | 0.110 |
Why?
|
| Trans-Activators | 4 | 2009 | 1624 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 2 | 2014 | 885 | 0.110 |
Why?
|
| Fertility | 1 | 2016 | 336 | 0.110 |
Why?
|
| Homeodomain Proteins | 3 | 2008 | 1125 | 0.110 |
Why?
|
| Genetic Techniques | 1 | 2014 | 152 | 0.110 |
Why?
|
| Rats, Mutant Strains | 2 | 2010 | 22 | 0.110 |
Why?
|
| Stromal Cells | 3 | 2013 | 825 | 0.110 |
Why?
|
| Models, Biological | 3 | 2012 | 3194 | 0.110 |
Why?
|
| User-Computer Interface | 1 | 2014 | 264 | 0.110 |
Why?
|
| Streptozocin | 1 | 2013 | 70 | 0.110 |
Why?
|
| Clonal Evolution | 1 | 2015 | 250 | 0.110 |
Why?
|
| Mesoderm | 2 | 2013 | 392 | 0.110 |
Why?
|
| Paraffin Embedding | 4 | 2018 | 223 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2017 | 5408 | 0.110 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 347 | 0.110 |
Why?
|
| Hyperinsulinism | 1 | 2013 | 86 | 0.100 |
Why?
|
| Duodenal Neoplasms | 1 | 2013 | 138 | 0.100 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2013 | 152 | 0.100 |
Why?
|
| Ampulla of Vater | 1 | 2013 | 160 | 0.100 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2015 | 460 | 0.100 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2015 | 376 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2010 | 2828 | 0.100 |
Why?
|
| Recombinational DNA Repair | 1 | 2012 | 79 | 0.100 |
Why?
|
| Poly A | 1 | 2012 | 96 | 0.100 |
Why?
|
| Patient Selection | 2 | 2021 | 2025 | 0.100 |
Why?
|
| Genes, erbB-1 | 1 | 2012 | 104 | 0.100 |
Why?
|
| Colonic Polyps | 1 | 2014 | 228 | 0.100 |
Why?
|
| Testicular Neoplasms | 1 | 2016 | 560 | 0.100 |
Why?
|
| Contraceptive Agents, Female | 1 | 2012 | 36 | 0.100 |
Why?
|
| Genetic Counseling | 1 | 2014 | 417 | 0.100 |
Why?
|
| Treatment Outcome | 12 | 2020 | 33737 | 0.100 |
Why?
|
| Survival Rate | 7 | 2019 | 12541 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 1017 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2019 | 2313 | 0.100 |
Why?
|
| Mice, Nude | 6 | 2017 | 4329 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2016 | 1418 | 0.090 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 2011 | 24 | 0.090 |
Why?
|
| Databases, Genetic | 1 | 2014 | 757 | 0.090 |
Why?
|
| Workflow | 3 | 2017 | 279 | 0.090 |
Why?
|
| Cytoplasm | 3 | 2008 | 702 | 0.090 |
Why?
|
| Everolimus | 4 | 2019 | 436 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 4 | 2019 | 402 | 0.090 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 339 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 1136 | 0.090 |
Why?
|
| Mice, Transgenic | 6 | 2020 | 4223 | 0.090 |
Why?
|
| Sarcoma | 3 | 2008 | 1839 | 0.090 |
Why?
|
| Pancreas | 1 | 2014 | 744 | 0.090 |
Why?
|
| Genetic Association Studies | 2 | 2018 | 1099 | 0.090 |
Why?
|
| Colonoscopy | 1 | 2014 | 522 | 0.090 |
Why?
|
| Tissue Array Analysis | 4 | 2016 | 757 | 0.090 |
Why?
|
| Multienzyme Complexes | 2 | 2008 | 226 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2020 | 1933 | 0.090 |
Why?
|
| Lymphatic Metastasis | 7 | 2019 | 4963 | 0.090 |
Why?
|
| Biomarkers | 6 | 2020 | 5051 | 0.090 |
Why?
|
| Hedgehog Proteins | 2 | 2010 | 440 | 0.090 |
Why?
|
| Transport Vesicles | 1 | 2010 | 7 | 0.090 |
Why?
|
| trans-Golgi Network | 1 | 2010 | 12 | 0.090 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 4960 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 2027 | 0.090 |
Why?
|
| Vacuoles | 1 | 2010 | 47 | 0.090 |
Why?
|
| Phenotype | 6 | 2019 | 6509 | 0.090 |
Why?
|
| Transgenes | 1 | 2012 | 576 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2012 | 694 | 0.090 |
Why?
|
| RNA, Long Noncoding | 1 | 2015 | 617 | 0.090 |
Why?
|
| Immunoblotting | 3 | 2017 | 895 | 0.090 |
Why?
|
| Cell Compartmentation | 1 | 2010 | 86 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 602 | 0.090 |
Why?
|
| Phagosomes | 1 | 2010 | 72 | 0.090 |
Why?
|
| Actins | 1 | 2012 | 602 | 0.090 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2014 | 350 | 0.090 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2009 | 107 | 0.080 |
Why?
|
| Benzamides | 6 | 2019 | 1879 | 0.080 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 16215 | 0.080 |
Why?
|
| Intestinal Mucosa | 3 | 2012 | 1105 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2006 | 1838 | 0.080 |
Why?
|
| Alleles | 3 | 2018 | 2600 | 0.080 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2009 | 20 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 2 | 2016 | 1456 | 0.080 |
Why?
|
| Endosomes | 1 | 2010 | 105 | 0.080 |
Why?
|
| Oncogenes | 1 | 2012 | 699 | 0.080 |
Why?
|
| Neoplasms, Experimental | 2 | 2014 | 784 | 0.080 |
Why?
|
| Hormone Antagonists | 1 | 2009 | 115 | 0.080 |
Why?
|
| Mifepristone | 1 | 2009 | 180 | 0.080 |
Why?
|
| Cell Membrane | 2 | 2010 | 878 | 0.080 |
Why?
|
| Chemoprevention | 2 | 2008 | 251 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 4 | 2015 | 4481 | 0.080 |
Why?
|
| Ovariectomy | 1 | 2010 | 371 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 3844 | 0.080 |
Why?
|
| Epigenesis, Genetic | 3 | 2017 | 1441 | 0.080 |
Why?
|
| Annexin A1 | 1 | 2008 | 41 | 0.080 |
Why?
|
| Rats, Zucker | 3 | 2014 | 59 | 0.080 |
Why?
|
| Cell Survival | 3 | 2010 | 3063 | 0.080 |
Why?
|
| Epidermal Growth Factor | 1 | 2010 | 439 | 0.080 |
Why?
|
| Cell Fusion | 1 | 2008 | 78 | 0.080 |
Why?
|
| Azoxymethane | 3 | 2014 | 44 | 0.080 |
Why?
|
| Genes, BRCA2 | 1 | 2010 | 322 | 0.080 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2008 | 111 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2010 | 1580 | 0.070 |
Why?
|
| Survival Analysis | 6 | 2017 | 9292 | 0.070 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 3339 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2013 | 3584 | 0.070 |
Why?
|
| CpG Islands | 2 | 2018 | 671 | 0.070 |
Why?
|
| Genes, BRCA1 | 1 | 2010 | 397 | 0.070 |
Why?
|
| Proportional Hazards Models | 5 | 2018 | 5101 | 0.070 |
Why?
|
| Gene Expression Regulation | 4 | 2012 | 4130 | 0.070 |
Why?
|
| Genes | 1 | 2009 | 606 | 0.070 |
Why?
|
| Cell Division | 4 | 2004 | 2657 | 0.070 |
Why?
|
| ErbB Receptors | 1 | 2016 | 2375 | 0.070 |
Why?
|
| Texas | 3 | 2018 | 6449 | 0.070 |
Why?
|
| Lysosomes | 1 | 2010 | 345 | 0.070 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2007 | 105 | 0.070 |
Why?
|
| Spermatogenesis | 1 | 2009 | 268 | 0.070 |
Why?
|
| GATA6 Transcription Factor | 1 | 2006 | 20 | 0.070 |
Why?
|
| Time Factors | 5 | 2019 | 13006 | 0.070 |
Why?
|
| Algorithms | 2 | 2017 | 3891 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2010 | 823 | 0.070 |
Why?
|
| PPAR gamma | 1 | 2008 | 225 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2007 | 142 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2019 | 1828 | 0.070 |
Why?
|
| Carcinogens | 3 | 2014 | 390 | 0.070 |
Why?
|
| Inhibitor of Apoptosis Proteins | 3 | 2013 | 202 | 0.070 |
Why?
|
| Interleukin-17 | 1 | 2008 | 255 | 0.070 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 4328 | 0.070 |
Why?
|
| Genetic Engineering | 1 | 2007 | 295 | 0.070 |
Why?
|
| Anticarcinogenic Agents | 1 | 2008 | 368 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 4831 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2010 | 809 | 0.060 |
Why?
|
| Genes, p16 | 1 | 2005 | 132 | 0.060 |
Why?
|
| Dyneins | 1 | 2005 | 33 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2010 | 520 | 0.060 |
Why?
|
| Immunotherapy | 4 | 2021 | 3557 | 0.060 |
Why?
|
| Mice, Mutant Strains | 3 | 2013 | 655 | 0.060 |
Why?
|
| Taxoids | 4 | 2012 | 1015 | 0.060 |
Why?
|
| Proteins | 1 | 2013 | 2043 | 0.060 |
Why?
|
| Imatinib Mesylate | 5 | 2012 | 1691 | 0.060 |
Why?
|
| Polymorphism, Genetic | 2 | 2008 | 1557 | 0.060 |
Why?
|
| Intestinal Polyposis | 1 | 2005 | 30 | 0.060 |
Why?
|
| Astrocytoma | 1 | 2007 | 326 | 0.060 |
Why?
|
| Cell Adhesion | 3 | 2018 | 1028 | 0.060 |
Why?
|
| Disease Models, Animal | 7 | 2013 | 7381 | 0.060 |
Why?
|
| Sigmoid Neoplasms | 1 | 2004 | 19 | 0.060 |
Why?
|
| Risk | 3 | 2016 | 1939 | 0.060 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 3035 | 0.060 |
Why?
|
| Leptin | 2 | 2016 | 306 | 0.060 |
Why?
|
| Wound Healing | 1 | 2009 | 749 | 0.060 |
Why?
|
| Inflammation | 2 | 2019 | 2518 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2013 | 1199 | 0.060 |
Why?
|
| Skin Neoplasms | 3 | 2018 | 4895 | 0.060 |
Why?
|
| Retinal Dehydrogenase | 2 | 2020 | 84 | 0.060 |
Why?
|
| Frozen Sections | 1 | 2004 | 113 | 0.060 |
Why?
|
| Phosphatidate Phosphatase | 1 | 2003 | 17 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2010 | 2137 | 0.060 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2019 | 327 | 0.060 |
Why?
|
| Mesna | 1 | 2003 | 67 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2016 | 2422 | 0.060 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2003 | 35 | 0.060 |
Why?
|
| Mass Spectrometry | 3 | 2017 | 722 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 4000 | 0.060 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2004 | 156 | 0.060 |
Why?
|
| Genes, erbB-2 | 1 | 2004 | 227 | 0.060 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 1059 | 0.060 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 2003 | 53 | 0.050 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2004 | 191 | 0.050 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2003 | 38 | 0.050 |
Why?
|
| Enzyme Inhibitors | 3 | 2008 | 1942 | 0.050 |
Why?
|
| Molecular Sequence Data | 4 | 2017 | 6685 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 1051 | 0.050 |
Why?
|
| Inhibins | 1 | 2003 | 116 | 0.050 |
Why?
|
| Lysophospholipids | 1 | 2003 | 148 | 0.050 |
Why?
|
| Hepatitis C, Chronic | 1 | 2008 | 471 | 0.050 |
Why?
|
| Ifosfamide | 1 | 2003 | 358 | 0.050 |
Why?
|
| Ischium | 1 | 2002 | 11 | 0.050 |
Why?
|
| Cell Shape | 2 | 2016 | 126 | 0.050 |
Why?
|
| Child | 6 | 2021 | 30559 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 1379 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 537 | 0.050 |
Why?
|
| Docosahexaenoic Acids | 1 | 2003 | 81 | 0.050 |
Why?
|
| Homeostasis | 2 | 2008 | 925 | 0.050 |
Why?
|
| Cyclins | 1 | 2004 | 467 | 0.050 |
Why?
|
| Carboplatin | 2 | 2019 | 880 | 0.050 |
Why?
|
| Hormones | 1 | 2023 | 285 | 0.050 |
Why?
|
| BRCA2 Protein | 2 | 2015 | 380 | 0.050 |
Why?
|
| Age Factors | 2 | 2009 | 5457 | 0.050 |
Why?
|
| Mass Screening | 2 | 2009 | 1552 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2004 | 506 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2021 | 2250 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5574 | 0.050 |
Why?
|
| Chromatography, Liquid | 2 | 2017 | 354 | 0.050 |
Why?
|
| Abnormalities, Multiple | 1 | 2007 | 1023 | 0.050 |
Why?
|
| Cancer Care Facilities | 2 | 2018 | 907 | 0.050 |
Why?
|
| Syndrome | 1 | 2004 | 1407 | 0.050 |
Why?
|
| Ascitic Fluid | 1 | 2021 | 84 | 0.050 |
Why?
|
| Exons | 2 | 2018 | 1383 | 0.050 |
Why?
|
| Transfection | 3 | 2016 | 3117 | 0.050 |
Why?
|
| Base Sequence | 4 | 2012 | 5437 | 0.050 |
Why?
|
| BRCA1 Protein | 2 | 2015 | 528 | 0.050 |
Why?
|
| Tretinoin | 1 | 2003 | 617 | 0.040 |
Why?
|
| NEDD8 Protein | 1 | 2020 | 23 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2017 | 2353 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 5866 | 0.040 |
Why?
|
| Pedigree | 3 | 2012 | 2042 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 511 | 0.040 |
Why?
|
| Pericardial Effusion | 1 | 2021 | 123 | 0.040 |
Why?
|
| Connexin 43 | 1 | 2019 | 46 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2016 | 875 | 0.040 |
Why?
|
| Protein Binding | 2 | 2016 | 3485 | 0.040 |
Why?
|
| Prevalence | 1 | 2007 | 3404 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2019 | 1723 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 57 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2019 | 164 | 0.040 |
Why?
|
| Hemizygote | 1 | 2019 | 16 | 0.040 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2019 | 230 | 0.040 |
Why?
|
| Chemokine CCL20 | 1 | 2019 | 39 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2006 | 1458 | 0.040 |
Why?
|
| Salivary Glands | 1 | 2019 | 139 | 0.040 |
Why?
|
| Chemokine CXCL1 | 1 | 2019 | 67 | 0.040 |
Why?
|
| Insulin | 2 | 2016 | 1483 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2019 | 98 | 0.040 |
Why?
|
| Protein Stability | 1 | 2020 | 377 | 0.040 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2019 | 87 | 0.040 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2018 | 27 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 164 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2019 | 189 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 3917 | 0.040 |
Why?
|
| Centrifugation | 1 | 2018 | 65 | 0.040 |
Why?
|
| Genome-Wide Association Study | 2 | 2017 | 2351 | 0.040 |
Why?
|
| Paclitaxel | 2 | 2019 | 2101 | 0.040 |
Why?
|
| Madin Darby Canine Kidney Cells | 1 | 2017 | 16 | 0.040 |
Why?
|
| Sulfones | 1 | 2019 | 145 | 0.040 |
Why?
|
| Indazoles | 1 | 2020 | 310 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2018 | 4644 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2014 | 2033 | 0.040 |
Why?
|
| Chemokines | 1 | 2019 | 290 | 0.040 |
Why?
|
| Acetanilides | 1 | 2017 | 17 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 741 | 0.040 |
Why?
|
| Cullin Proteins | 1 | 2017 | 38 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2014 | 1810 | 0.040 |
Why?
|
| Cadherins | 2 | 2013 | 657 | 0.040 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2018 | 161 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 5056 | 0.040 |
Why?
|
| Chromothripsis | 1 | 2017 | 11 | 0.040 |
Why?
|
| Abdomen | 1 | 2019 | 347 | 0.040 |
Why?
|
| Morphogenesis | 1 | 2018 | 319 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 659 | 0.040 |
Why?
|
| Pseudopodia | 1 | 2016 | 26 | 0.030 |
Why?
|
| Molecular Probes | 1 | 2017 | 71 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2019 | 622 | 0.030 |
Why?
|
| Risk Assessment | 3 | 2018 | 6764 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2020 | 904 | 0.030 |
Why?
|
| Azepines | 1 | 2017 | 134 | 0.030 |
Why?
|
| Regeneration | 1 | 2019 | 284 | 0.030 |
Why?
|
| Lectins | 1 | 2016 | 148 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 2 | 2008 | 167 | 0.030 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2017 | 105 | 0.030 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2016 | 66 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2018 | 1049 | 0.030 |
Why?
|
| Organoplatinum Compounds | 2 | 2012 | 704 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2019 | 562 | 0.030 |
Why?
|
| Embryo Loss | 1 | 2016 | 39 | 0.030 |
Why?
|
| Co-Repressor Proteins | 2 | 2008 | 120 | 0.030 |
Why?
|
| Adiposity | 1 | 2018 | 238 | 0.030 |
Why?
|
| p21-Activated Kinases | 1 | 2016 | 131 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2008 | 2635 | 0.030 |
Why?
|
| Caco-2 Cells | 2 | 2006 | 161 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2017 | 589 | 0.030 |
Why?
|
| Gonadotropins | 1 | 2016 | 52 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2019 | 494 | 0.030 |
Why?
|
| Dogs | 1 | 2017 | 1160 | 0.030 |
Why?
|
| Quality Control | 1 | 2017 | 461 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 139 | 0.030 |
Why?
|
| Organs at Risk | 1 | 2019 | 559 | 0.030 |
Why?
|
| United States | 4 | 2019 | 15861 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2019 | 701 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 274 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 396 | 0.030 |
Why?
|
| Intestine, Small | 1 | 2019 | 522 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 1322 | 0.030 |
Why?
|
| Tissue Embedding | 1 | 2015 | 28 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2016 | 137 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 1246 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2015 | 45 | 0.030 |
Why?
|
| Postmenopause | 2 | 2010 | 375 | 0.030 |
Why?
|
| Models, Animal | 1 | 2018 | 657 | 0.030 |
Why?
|
| Glutathione Transferase | 2 | 2008 | 367 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 474 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2015 | 170 | 0.030 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2015 | 85 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 3949 | 0.030 |
Why?
|
| Rectum | 1 | 2017 | 480 | 0.030 |
Why?
|
| Caloric Restriction | 1 | 2016 | 88 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 2016 | 295 | 0.030 |
Why?
|
| Adiponectin | 1 | 2016 | 143 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 361 | 0.030 |
Why?
|
| Body Composition | 1 | 2018 | 606 | 0.030 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2015 | 162 | 0.030 |
Why?
|
| Pregnancy | 3 | 2016 | 8130 | 0.030 |
Why?
|
| Mycosis Fungoides | 1 | 2018 | 341 | 0.030 |
Why?
|
| SMARCB1 Protein | 1 | 2015 | 107 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2017 | 579 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2010 | 1608 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 274 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2017 | 531 | 0.030 |
Why?
|
| PPAR-beta | 1 | 2014 | 14 | 0.030 |
Why?
|
| Heterozygote | 2 | 2008 | 1056 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 338 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2015 | 219 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 1553 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 547 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2015 | 264 | 0.030 |
Why?
|
| Drug Approval | 1 | 2015 | 174 | 0.030 |
Why?
|
| Isoenzymes | 2 | 2009 | 648 | 0.030 |
Why?
|
| Weight Loss | 1 | 2018 | 628 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2017 | 668 | 0.030 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2013 | 17 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 3530 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 2014 | 116 | 0.030 |
Why?
|
| Gene Editing | 1 | 2016 | 229 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 709 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 323 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2016 | 385 | 0.030 |
Why?
|
| Vaginal Smears | 1 | 2014 | 166 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1097 | 0.030 |
Why?
|
| DNA Polymerase II | 1 | 2013 | 58 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 314 | 0.030 |
Why?
|
| Incidence | 2 | 2019 | 5824 | 0.030 |
Why?
|
| Cell Line | 2 | 2013 | 5338 | 0.030 |
Why?
|
| Triazoles | 1 | 2017 | 627 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2014 | 232 | 0.030 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2013 | 117 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2013 | 120 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 336 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 2013 | 208 | 0.030 |
Why?
|
| Microbiota | 1 | 2019 | 547 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2016 | 362 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2014 | 437 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2012 | 84 | 0.030 |
Why?
|
| Microdissection | 1 | 2012 | 85 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2015 | 1685 | 0.030 |
Why?
|
| Systems Biology | 1 | 2012 | 115 | 0.020 |
Why?
|
| Vimentin | 1 | 2013 | 252 | 0.020 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 880 | 0.020 |
Why?
|
| Binding Sites | 1 | 2016 | 2255 | 0.020 |
Why?
|
| Receptor, Notch1 | 1 | 2013 | 217 | 0.020 |
Why?
|
| RNA Interference | 1 | 2016 | 1388 | 0.020 |
Why?
|
| Histones | 1 | 2019 | 1513 | 0.020 |
Why?
|
| Placenta | 1 | 2016 | 561 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2012 | 168 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2013 | 407 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2019 | 1471 | 0.020 |
Why?
|
| Subcutaneous Fat | 1 | 2011 | 65 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2014 | 550 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2016 | 1138 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2013 | 384 | 0.020 |
Why?
|
| Recurrence | 2 | 2010 | 4878 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2012 | 262 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 1525 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 1121 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2019 | 4019 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2008 | 7783 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 427 | 0.020 |
Why?
|
| Survival | 1 | 2010 | 183 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 4492 | 0.020 |
Why?
|
| Family | 1 | 2014 | 783 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2010 | 111 | 0.020 |
Why?
|
| Adenoma | 2 | 2005 | 740 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2011 | 188 | 0.020 |
Why?
|
| Smoothened Receptor | 1 | 2010 | 53 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2011 | 188 | 0.020 |
Why?
|
| Dasatinib | 1 | 2014 | 881 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2014 | 1140 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 1034 | 0.020 |
Why?
|
| Fertility Preservation | 1 | 2012 | 151 | 0.020 |
Why?
|
| Genes, cdc | 1 | 2010 | 84 | 0.020 |
Why?
|
| Research Design | 1 | 2017 | 1569 | 0.020 |
Why?
|
| Microvessels | 1 | 2010 | 145 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2010 | 162 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 1054 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2002 | 2665 | 0.020 |
Why?
|
| Ribonucleoproteins, Small Nucleolar | 1 | 2009 | 10 | 0.020 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2013 | 706 | 0.020 |
Why?
|
| Heterografts | 1 | 2012 | 738 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 448 | 0.020 |
Why?
|
| Phosphoglycerate Kinase | 1 | 2009 | 23 | 0.020 |
Why?
|
| Histone Deacetylase 1 | 1 | 2009 | 63 | 0.020 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2009 | 29 | 0.020 |
Why?
|
| Histone Deacetylase 2 | 1 | 2009 | 39 | 0.020 |
Why?
|
| Decidua | 1 | 2010 | 152 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2012 | 909 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 822 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 2315 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 2115 | 0.020 |
Why?
|
| Ribosomal Proteins | 1 | 2009 | 134 | 0.020 |
Why?
|
| Epoxide Hydrolases | 1 | 2008 | 55 | 0.020 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2008 | 67 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2014 | 1192 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2008 | 210 | 0.020 |
Why?
|
| Chromones | 1 | 2008 | 121 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2009 | 262 | 0.020 |
Why?
|
| Diethylstilbestrol | 1 | 2008 | 165 | 0.020 |
Why?
|
| Transcobalamins | 1 | 2007 | 6 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2008 | 122 | 0.020 |
Why?
|
| Brain | 2 | 2014 | 4208 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2008 | 73 | 0.020 |
Why?
|
| Cytosol | 1 | 2008 | 267 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 469 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2009 | 201 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2008 | 106 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2007 | 168 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2010 | 691 | 0.020 |
Why?
|
| China | 1 | 2009 | 636 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 1432 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 503 | 0.020 |
Why?
|
| Androstadienes | 1 | 2008 | 172 | 0.020 |
Why?
|
| Corpus Callosum | 1 | 2007 | 127 | 0.020 |
Why?
|
| Metabolome | 1 | 2010 | 355 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 1461 | 0.020 |
Why?
|
| Technetium Compounds | 1 | 2006 | 12 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 678 | 0.020 |
Why?
|
| Tuberous Sclerosis | 1 | 2008 | 145 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2017 | 17061 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 1584 | 0.020 |
Why?
|
| Morpholines | 1 | 2008 | 296 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 2331 | 0.020 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2005 | 16 | 0.020 |
Why?
|
| ROC Curve | 1 | 2009 | 1248 | 0.020 |
Why?
|
| Linoleic Acids | 1 | 2005 | 32 | 0.020 |
Why?
|
| Body Weight | 1 | 2011 | 1307 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 4761 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2005 | 107 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2013 | 2035 | 0.020 |
Why?
|
| Base Pair Mismatch | 1 | 2005 | 82 | 0.020 |
Why?
|
| Cytoplasmic Dyneins | 1 | 2005 | 6 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 659 | 0.020 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2005 | 35 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 1312 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2008 | 487 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 3045 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2006 | 655 | 0.020 |
Why?
|
| Intestinal Polyps | 1 | 2005 | 79 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2005 | 726 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2009 | 1163 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2009 | 617 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2004 | 329 | 0.010 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2004 | 109 | 0.010 |
Why?
|
| Peptide Library | 1 | 2004 | 148 | 0.010 |
Why?
|
| Myometrium | 1 | 2004 | 82 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2004 | 251 | 0.010 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2005 | 226 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 590 | 0.010 |
Why?
|
| Decision Trees | 1 | 2004 | 181 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2006 | 1430 | 0.010 |
Why?
|
| Antigens | 1 | 2004 | 281 | 0.010 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2005 | 507 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2004 | 399 | 0.010 |
Why?
|
| Bevacizumab | 1 | 2007 | 967 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2008 | 1368 | 0.010 |
Why?
|
| Calbindin 2 | 1 | 2003 | 43 | 0.010 |
Why?
|
| Retinoic Acid 4-Hydroxylase | 1 | 2003 | 16 | 0.010 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2003 | 30 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 350 | 0.010 |
Why?
|
| Prostaglandin D2 | 1 | 2003 | 26 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2003 | 237 | 0.010 |
Why?
|
| Chromans | 1 | 2003 | 28 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2003 | 257 | 0.010 |
Why?
|
| Immune System | 1 | 2004 | 275 | 0.010 |
Why?
|
| Transglutaminases | 1 | 2003 | 97 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2008 | 1570 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 300 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 749 | 0.010 |
Why?
|
| Azacitidine | 1 | 2009 | 1218 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 727 | 0.010 |
Why?
|
| Placebos | 1 | 2003 | 442 | 0.010 |
Why?
|
| Skin | 1 | 2007 | 1271 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2003 | 210 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 938 | 0.010 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2003 | 367 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2008 | 1654 | 0.010 |
Why?
|
| Antibodies | 1 | 2004 | 809 | 0.010 |
Why?
|
| Smoking | 1 | 2011 | 2555 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 693 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 2650 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2004 | 875 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2002 | 354 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2004 | 1129 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 1012 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 2008 | 1046 | 0.010 |
Why?
|
| Telomerase | 1 | 2003 | 547 | 0.010 |
Why?
|
| Intellectual Disability | 1 | 2007 | 1065 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 5694 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2004 | 1741 | 0.010 |
Why?
|
| Kidney | 1 | 2008 | 2121 | 0.010 |
Why?
|
| Chromatin | 1 | 2005 | 1046 | 0.010 |
Why?
|
| Genes, ras | 1 | 2002 | 679 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2004 | 2311 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 3028 | 0.010 |
Why?
|
| Peptides | 1 | 2004 | 1504 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 1063 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 4567 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2004 | 1580 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 3444 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 3409 | 0.010 |
Why?
|